IP Library Granted Patent US 8,377,466
Granted Patent B2
US 8,377,466 · App. 10/971,684 · Granted Feb 19, 2013

Adhesive tissue repair patch

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,466
App. No.
10/971,684
Granted
Feb 19, 2013
Kind
B2
Abstract

A method of tissue repair is provided using a biocompatible nonimmunogenic adhesive composition. The adhesive composition comprises collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Kits for use in carrying out the method of the invention are also provided, as are pretreated surgically acceptable patches that have been coated with the aforementioned adhesive composition.

Claims (15)

1. A mesh for use in the repair of herniated tissue comprising a mesh and a coating composition including:

(a) a naturally occurring hydrophilic polymer selected from proteins, polysaccharides, and glycosaminoglycans, wherein the naturally occurring hydrophilic polymer is not methylated collagen;

(b) a first synthetic polymer having m nucleophilic groups, wherein m≧2;

(c) a second synthetic polymer having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds, wherein n≧2; and

wherein each of the first synthetic polymer and the second synthetic polymer is poly (alkylene oxide) and crosslinking of the coating composition results in a biocompatible, crosslinked matrix.

2. The mesh of claim 1 , wherein the first synthetic polymer and the second synthetic polymer are hydrophilic.

3. The mesh of claim 1 , wherein m+n is 5 or more.

4. The mesh of claim 1 , wherein each of the first synthetic polymer and the second synthetic polymer is nonimmunogenic.

5. The mesh of claim 1 , wherein the naturally occurring hydrophilic polymer is selected from nonfibrillar collagen, succinylated collagen, fibrillar collagen, denatured collagen and combinations thereof.

6. The mesh of claim 5 , wherein the nonfibrillar collagen is selected from type IV collagen, type VI collagen, and type VII collagen.

7. The mesh of claim 2 , wherein the first synthetic polymer and the second synthetic polymer are polyalkylene oxides.

8. The mesh of claim 7 , wherein the first synthetic polymer and the second synthetic polymer are polyethylene glycol.

9. The mesh of claim 1 , wherein the nucleophilic groups of the first synthetic polymer can be the same or different and are —NH 2 , —SH, —OH, —PH 2 , or —CO—NH—NH 2 .

10. The mesh of claim 1 , wherein the coating composition further comprises a biologically active agent.

11. The mesh of claim 1 , wherein the electrophilic groups are a succinimidyl ester group, a succinimidyl carbonate group, and a maleimidyl group, —COOH, —CHO, —N═C═O or —SO 2 CH—CH 2 .

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Sep 4, 2013
From: WELLS FARGO FOOTHILL, LLC
To: ANGIOTECH PHARMACEUTICALS, INC.; ANGIOTECH AMERICA, INC.; SURGICAL SPECIALTIES CORPORATION (US), INC., FORMERLY KNOWN AS ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; ANGIOTECH INTERNATIONAL HOLDINGS CORP.
Reel/Frame 031157/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2010
From: ANGIOTECH PHARMACEUTICALS (US), INC.
To: ANGIODEVICE INTERNATIONAL GMBH
Reel/Frame 024743/0208 →
SECURITY AGREEMENT Recorded Mar 2, 2009
From: ANGIOTECH PHARMACEUTICALS, INC.; AFMEDICA, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH CAPITAL, LLC; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; CRIMSON CARDINAL CAPITAL, LLC; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; NEUCOLL INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; 0741693 BRITISH COLUMBIA LTD.; 3091796 NOVA SCOTIA COMPANY; ANGIOTECH INTERNATIONAL HOLDINGS, CORP.; ANGIOTECH INVESTMENT PARTNERSHIP
To: WELLS FARGO FOOTHILL, LLC AS AGENT
Reel/Frame 022329/0310 →
RELEASE OF SECURITY INTEREST Recorded Dec 11, 2006
From: CREDIT SUISSE
To: ANGIOTECH PHARMACEUTICALS (US), INC.
Reel/Frame 018606/0616 →
SECURITY AGREEMENT Recorded Apr 11, 2006
From: ANGIOTECH PHARMACEUTICALS (US), INC.
To: CREDIT SUISSE, AS COLLATERAL AGENT
Reel/Frame 017448/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2006
From: ANGIOTECH BIOMATERIALS CORPORATION
To: ANGIOTECH PHARMACEUTICALS (US), INC.
Reel/Frame 017299/0010 →
CHANGE OF NAME Recorded Jun 21, 2005
From: COHESION TECHNOLOGIES, INC.
To: ANGIOTECH BIOMATERIALS CORP.
Reel/Frame 016369/0932 →